Cortical GABA Concentrations in Insomnia
Completed
Conditions studied: Insomnia, Major Depression
In brief
Disturbances in the amino acid neurotransmitter (AANt), gamma-amino butyric acid (GABA) function are hypothesized to contribute to the neurobiology of Major Depressive Disorder (MDD) and insomnia. The principal objective of this project is to use magnetic resonance spectroscopy (MRS) to provide the first in vivo characterization of cortical GABA levels in individuals with primary insomnia, and to determine whether subjects with MDD, achieving a partial response with selective serotonin reuptake inhibitor treatment but still experiencing significant residual symptoms including insomnia, have altered levels of this neurotransmitter. The investigators are also exploring the correlation between cortical AANt levels and abnormalities in sleep parameters in primary insomnia and as a residual symptom of major depression.
Key facts
- Study ID
- NCT00765752
- Run by
- Yale University
- People needed
- 23
- Starts
- 2007-11-01
- Expected to finish
- 2011-06-01
- Last updated by the study team
- 2013-01-21
Who can join
Age: 25 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Yale Depression Research Program — New Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.